Contact

Click here for a confidential contact or call:

1-347-417-2192

Pharma Fraud

This archive displays posts tagged as relevant to pharmaceutical fraud. You may also be interested in our pages:

Page 27 of 39

Fraudster of the Week -- TRICARE Fraudster Joseph Baumiller

Posted  10/20/17
By the C|C Whistleblower Lawyer Team On Tuesday, 38-year-old Joseph Baumiller of Dallas, Texas pleaded guilty to one count of conspiracy to defraud TRICARE, the health care program serving military members and their families. Baumiller, the former president of Trilogy Pharmacy, admitted to conspiring with several marketers, physicians, and other pharmacists to orchestrate a scheme involving the payment of kickbacks...

Tagged in: Anti-Kickback and Stark, Catch of the Week, Compounding Pharmacy Fraud, Other Government Health Programs, Pharma Fraud,

Read More

Former DEA Agent Alleges Opioid Crisis Fueled by Drug Companies

Posted  10/16/17
By the C|C Whistleblower Lawyer Team As reported in CBS News, the Washington Post and other news outlets A former employee of the Drug Enforcement Administration (DEA) said in an interview that efforts to stem the growing opioid epidemic in the U.S. were derailed by pressure from large pharmaceutical companies and Congress. Joe Rannazzisi told CBS that major distributors allowed drugs to be obtained by rogue...

Tagged in: Pharma Fraud,

Read More

Aegerion Pharmaceuticals Will Pay More Than $40 Million to Resolve Investigations Into Its Marketing and Sales Practices

Posted  09/25/17
Aegerion Pharmaceuticals will plead guilty to charges concerning its prescription drug, Juxtapid, the Department of Justice announced on Friday.  According to the Justice Department’s press release: Aegerion introduced Juxtapid into interstate commerce that was misbranded because, among other things, Aegerion failed to comply with a Risk Evaluation and Mitigation Strategy (REMS).  The resolution also...

Tagged in: FCA Federal, FDA Fraud, Pharma Fraud, Securities Fraud, Whistleblower Case, Whistleblower Rewards,

Read More

Health Insurers May Be Contributing to the Opioid Crisis in the United States

Posted  09/18/17
By the C|C Whistleblower Lawyer Team An article in the New York Times describes the role health insurers may be playing in perpetuating the opioid crisis in the United States. The argument is that health insurers are limiting access to pain medications that have a lower risk of dependency. The reason is that opioid drugs are generally cheaper and less risky alternatives are more expensive. The New York State...

Tagged in: Healthcare Fraud, Pharma Fraud,

Read More

DOJ Catch of the Week -- Novo Nordisk Inc.

Posted  09/8/17
By the C|C Whistleblower Lawyer Team This week's Department of Justice "Catch of the Week" goes to Novo Nordisk Inc. On Tuesday, the company agreed to pay $58.65 million to settle charges it violated the False Claims Act and Food, Drug, and Cosmetic Act by failing to comply with the FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) for its Type II diabetes medication Victoza. The New Jersey based...

Tagged in: Catch of the Week, FCA Federal, FDA Fraud, Pharma Fraud,

Read More

September 5, 2017

Novo Nordisk, Inc. has agreed to $1.1 million to resolve claims that its diabetes drug Victoza was unlawfully promoted for off-label use in violation of the California Insurance Frauds Prevention Act.  The claims were brought in a whistleblower action under that act filed by former Novo Nordisk researcher Peter Dastous, who will receive a share of the settlement.  CA

Tagged in: Off-Label and Unapproved Use, Pharma Fraud, Private Insurance Whistleblower Reward Programs, Whistleblower Case, Whistleblower Rewards,

August 28, 2017

Mary Inman appeared as a special guest on RAC Monitor’s “Monitor Monday” radio broadcast “Pharma on Pharma:  Sanofi-Aventis Blows the Whistle on Mylan $465 Million False Claims Settlement.”  Mary’s remarks begin at 22:11 minutes into the program.

Tagged in: Pharma Fraud, Whistleblower Case, Whistleblower Eligibility,

Mylan Agrees to Pay $465 Million in a False Claims Act Settlement

Posted  08/21/17
By the C|C Whistleblower Lawyer Team Last Friday, the Department of Justice (“DOJ”) announced a $465 million settlement with Mylan, Inc. to resolve claims that it violated the False Claim Act. The suit was brought by a whistleblower under the False Claims Act qui tam provisions and involved the alleged improper misclassification of the EpiPen as a generic drug to avoid paying rebates owed mainly to Medicaid....

Tagged in: Drug and DME Pricing, Medicaid, Pharma Fraud, Whistleblower Case, Whistleblower Eligibility, Whistleblower Rewards,

Read More

DOJ Catch of the Week -- Mylan

Posted  08/18/17
By the C|C Whistleblower Lawyer Team This week's Department of Justice "Catch of the Week" goes to Mylan Inc. and Mylan Specialty L.P. Yesterday, the pharmaceutical companies agreed to pay $465 million to settle charges they violated the False Claims Act by purposely misclassifying EpiPen as a generic drug to avoid paying higher Medicaid rebates. In announcing the settlement, the government stressed its "unwavering...

Tagged in: Catch of the Week, Drug and DME Pricing, FCA Federal, Medicaid, Pharma Fraud, Whistleblower Eligibility, Whistleblower Rewards,

Read More

August 18, 2017

Illinois and other states announced a $465 million settlement between the federal government and states with Mylan Inc. and its wholly-owned subsidiary, Mylan Specialty L.P. (Mylan), to resolve allegations that Mylan knowingly underpaid rebates owed to the Medicaid program for EpiPen® and EpiPen Jr.® (EpiPen) dispensed to Medicaid beneficiaries. The settlement resolves allegations that from July 29, 2010 to March 31, 2017, Mylan submitted false statements to the Centers for Medicare and Medicaid Services (CMS) that incorrectly classified EpiPens under terms defined in the Rebate Statute and Rebate Agreement. Mylan also failed to report a "Best Price" to CMS for EpiPens, as directed by the same statute. As a result, Mylan submitted false statements related to EpiPens to CMS and the states for Medicaid rebate purposes and underpaid EpiPen rebates to the state Medicaid programs. IL, IA

Tagged in: Drug and DME Pricing, Healthcare Fraud, Medicaid, Pharma Fraud,

1 … 25 26 27 28 29 … 39

Newsletter

Subscribe to receive email updates from the Constantine Cannon blogs

Sign up for: